Signaling Pathways in Breast Cancer
Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance
- 1st Edition - October 1, 2026
- Latest edition
- Editors: Sumel Ashique, Neeraj Mishra, Farzad Taghizadeh-Hesary, Maria Vliora
- Language: English
Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance provides an in-depth exploration of the complex molecular mechan… Read more
Description
Description
Key features
Key features
- Provides a detailed exploration of critical signaling pathways such as PI3K/Akt, MAPK, JAK/STAT, and Notch, elucidating their roles in tumor initiation, progression, and resistance to therapy
- Discusses FDA-approved targeted therapies and emerging treatment strategies, including immunotherapy and personalized medicine
- Addresses mechanisms of drug resistance and potential strategies for overcoming resistance
- Includes case studies and biomarker-based approaches that link molecular mechanisms to clinical outcomes
- Offers insights into ongoing clinical trials and future directions in breast cancer therapy
Readership
Readership
Table of contents
Table of contents
2. Emerging Molecular Targets in Breast Cancer Therapy
3. Role of Tumor Microenvironment in Breast Cancer Development
4. Molecular Subtypes of Breast Cancer and Their Clinical Significance
5. Key Signaling Pathways in Breast Cancer Progression
6. RNA-Based Therapies: miRNA and siRNA in Breast Cancer Treatment
7. Targeting Angiogenesis: VEGF and Its Inhibitors
8. Antibody-Drug Conjugates (ADCs) in Breast Cancer Treatment
9. Small Molecule Kinase Inhibitors: Current Status and Future Directions
10. Nanotechnology and Precision Drug Delivery for Breast Cancer
11. MDR and Strategies to Overcome Therapy Failure
12. Combination Therapies for Overcoming Resistance in Breast Cancer
13. Targeting Autophagy in Overcoming Multidrug Resistance
14. Role of Biomarker-Based Therapeutic Approaches
15. Role of CRISPR in Triple Negative Breast Cancer
16. ERK Signaling and Breast Cancer
17. Artificial Intelligence in Breast Cancer Therapy
18. Role of Microbiota in Breast Cancer Progression and Therapy
19. Heterogeneity and Drug Resistance in Breast Cancer
20. Advancement Therapeutic Approaches in Drug Resistance Breast Cancer Management
21. Bridging Theory and Practice in Breast Cancer: Case Studies and Clinical Insights
22. Challenges and Innovations in Therapeutic Strategies in Treatment of Breast Cancer
Product details
Product details
- Edition: 1
- Latest edition
- Published: October 1, 2026
- Language: English
About the editors
About the editors
SA
Sumel Ashique
Sumel Ashique has been working as an assistant professor at Bengal College of Pharmaceutical Sciences & Research, Durgapur West Bengal, India, West Bengal, India. He has several years of teaching experience. He has achieved 70+ publications of International and national accredited reputed journals . He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He has also 6 granted patents from IP and Australia & dozens of book chapters have been submitted to well-known publishers.
NM
Neeraj Mishra
Dr. Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Gwalior. He has extensive teaching and research experience in pharmaceutics, with particular expertise in novel drug delivery systems, localized and targeted drug delivery, and nanocarrier-based therapeutics for cancer and neurodegenerative disorders. His research interests focus on advanced pharmaceutical formulations and controlled delivery approaches aimed at improving therapeutic outcomes.
Dr. Mishra has supervised postgraduate and doctoral research scholars and has contributed widely to academic literature through research publications, books, and book chapters with leading international publishers. He is also associated with innovation in pharmaceutical sciences through patented research contributions. Over the course of his career, he has received several academic and scientific recognitions for his contributions to teaching, research, and pharmaceutical education. He has additionally been recognized internationally for his research impact and scholarly contributions in the field of pharmaceutical sciences.
FT
Farzad Taghizadeh-Hesary
Dr. Farzad Taghizadeh-Hesary is an Assistant Professor of Radiation Oncology at Iran University of Medical Sciences, specializing in oncology, radiobiology, and cancer metabolism. He earned his M.D. in 2015 from IUMS and completed a Radiation Oncology residency at Shahid Beheshti University of Medical Sciences, ranking among the top graduates nationally. His thesis examined late toxicities after IMRT for nasopharyngeal carcinoma, reflecting a commitment to precision radiotherapy.
His expertise spans clinical and academic oncology, with a focus on tumor microenvironment and mitochondrial metabolism in cancer. He has published more than 80 peer-reviewed articles and serves on editorial boards including BMC Cancer and PLoS ONE. Awards include the Razi Medical Science Research Prize and the Outstanding Reviewer Award from JCO Clinical Cancer Informatics; Publons Academy ranked him the top global Radiation Oncology reviewer in 2021.
His research centers on personalized radiotherapy, cancer immunotherapy, and metabolic interventions targeting mitochondrial dysfunction, advancing translational oncology
MV